GHRP-2 vs Tesofensine
Head-to-head comparison of GHRP-2 and Tesofensine for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Ghrp 2 | Tesofensine |
|---|---|---|
| Category | Growth Hormone Secretagogue | Weight Loss / Reuptake Inhibitor |
| Mechanism | GHRP-2 (C45H55N9O6) binds to and activates ghrelin (GH secretagogue) receptors on pituitary somatotrophs, triggering robust pulsatile GH release. | Tesofensine inhibits the presynaptic reuptake of serotonin, norepinephrine, and dopamine, increasing synaptic concentrations of all three monoamines. |
| Evidence Rating | C — Phase I–II Clinical Trials | C — Phase II–III Clinical Trials |
| Clinical Status | Approved in Japan for GH deficiency diagnosis; research-only elsewhere | Phase 3 clinical trials (Saniona). Phase 2 completed with significant weight loss results. |
| Safety Profile | Well tolerated in clinical trials with placebo-like safety profile at therapeutic ranges; May increase appetite (less than GHRP-6) | Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses; Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea |
| Molecular Weight | ~817.0 g/mol | ~397.5 g/mol |
| Half-Life | ~15–60 minutes | N/A |
Overview
GHRP-2 and Tesofensine are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
GHRP-2 — Mechanism & Evidence
GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone secretagogue (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, MW ~817.97 g/mol) that stimulates potent, dose-dependent GH release via the ghrelin receptor (GHS-R). It is considered more potent than GHRP-6 with less appetite stimulation. Approved in Japan as a diagnostic agent for GH deficiency (pralmorelin), it has been used clinically in GH-deficient children for 8-24 months with maintained efficacy on growth velocity. Clinical studies show a placebo-like safety profile at therapeutic doses.
Key claims: Potent growth hormone release; Diagnostic tool for GH deficiency; Sustained efficacy in long-term use.
Tesamorelin 10mg
10mg
Tesofensine — Mechanism & Evidence
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Alzheimer's and Parkinson's disease. The compound was developed by NeuroSearch A/S and later licensed to Saniona, which is pursuing Phase 3 trials.
Key claims: Produces significant weight loss (~10% body weight); Suppresses appetite and reduces caloric intake; Increases resting metabolic rate.
Shared Research Applications
These peptides target different research areas. GHRP-2 focuses on Body Composition, while Tesofensine targets Weight Loss, Appetite Suppression.
Safety Considerations
GHRP-2: Well tolerated in clinical trials with placebo-like safety profile at therapeutic ranges May increase appetite (less than GHRP-6) Can elevate cortisol and prolactin levels (less than GHRP-6)
Tesofensine: Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea Psychiatric effects reported: anxiety, mood changes (consistent with monoamine reuptake inhibitors)
Shop Research Peptides
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesofensine: Triple Monoamine Reuptake Inhibitor in Metabolic Research
Tesofensine triple monoamine reuptake inhibitor metabolic research preclinical evidence mechanisms safety
Ipamorelin vs GHRP-2: Which Offers More Targeted GH Release?
Ipamorelin and GHRP-2 both stimulate growth hormone release via the ghrelin receptor, but Ipamorelin provides more selective action with minimal impact on other hormones like ACTH and cortisol. GHRP-2 delivers stronger GH pulses alongside broader endocrine effects. Combining them can enhance overall GH output through additive receptor stimulation.